What changed: Cancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma)
Every dated change on the records linked to Cancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
2024 · 2
2023 · 5
- 2023GuidelineCancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma)Guideline ESMO Clinical Practice Guideline on cancer of unknown primary 2023: Actionable alterations
Tumour-agnostic therapies: pembrolizumab or nivolumab for MSI-high or high tumour mutational burden, NTRK inhibitors, BRAF and MEK inhibitors, HER2-directed therapy.
- 2023GuidelineCancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma)Guideline ESMO Clinical Practice Guideline on cancer of unknown primary 2023: First line, fit patients
Platinum-based doublet (carboplatin-paclitaxel or gemcitabine-cisplatin) for three cycles, then continuation or a switch to molecularly guided therapy where an actionable alteration is found (CUPISCO).
- 2023GuidelineCancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma)Guideline ESMO Clinical Practice Guideline on cancer of unknown primary 2023: Poor performance status
Best supportive care with early palliative care involvement.
- 2023GuidelineCancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma)Guideline ESMO Clinical Practice Guideline on cancer of unknown primary 2023: Second line
Alternative chemotherapy, PD-1 antibody if not given (nivolumab approved in Japan), or trial entry; trials of antibody-drug conjugates and immunotherapy combinations.
- 2023GuidelineCancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma)Guideline ESMO Clinical Practice Guideline on cancer of unknown primary 2023: Work-up
Exclude favourable subsets; comprehensive genomic profiling of tissue or plasma; assess performance status and lactate dehydrogenase.